Core Viewpoint - Fosun Pharma's subsidiary, Fosun Kairui, has had its drug registration application for FKC889 accepted by the National Medical Products Administration for treating relapsed or refractory precursor B-cell acute lymphoblastic leukemia in adult patients [1] Group 1: Product Development - FKC889 is a CAR-T cell therapy product targeting CD19, developed through technology transfer from Kite Pharma, a subsidiary of Gilead Sciences [1] - Tecartus, the original product, was approved for market in the US and Europe in July and December 2020 respectively [1] - As of September 24, 2025, FKC889 is in the bridging clinical trial phase for another indication, treating adult patients with relapsed or refractory mantle cell lymphoma after second-line treatment [1] Group 2: Financial Investment - The cumulative R&D investment for FKC889 as of August 2025 is approximately RMB 183 million (unaudited) [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品註冊申請獲受理的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年9 月2 4 日 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工董事為嚴佳女士。 ...

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Kerry (Shanghai) Biotechnology Co., Ltd., has had its drug registration application for Brexucabtagene Autoleucel injection accepted by the National Medical Products Administration, targeting adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) [1] Group 1 - The drug application is specifically for treating adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) [1] - Another indication for the product, aimed at adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL) who have previously undergone second-line or higher treatment, is currently in the bridging clinical trial phase within mainland China (excluding Hong Kong, Macau, and Taiwan) [1]

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Kairui, has received acceptance from the National Medical Products Administration for the drug registration application of FKC889, aimed at treating relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) in adult patients [1] Group 1 - The product FKC889 is a targeted CD19 CAR-T cell therapy developed and localized in China based on the Tecartus technology licensed from Kite Pharma, a subsidiary of Gilead Sciences [1] - Tecartus was approved for market launch in the United States and Europe in July and December 2020, respectively [1]

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Kairui, has received acceptance from the National Medical Products Administration for the drug registration application of FKC889, aimed at treating relapsed or refractory precursor B-cell acute lymphoblastic leukemia in adult patients [1] Group 1 - The product FKC889 is a targeted CD19 CAR-T cell therapy developed and localized in China based on the technology transferred from Kite Pharma, a subsidiary of Gilead Sciences [1] - Tecartus, the original product, was approved for market in the US and Europe in July and December 2020 respectively [1]

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Kerry, has received acceptance from the National Medical Products Administration for the drug registration application of Brukinsa injection (project code: FKC889), aimed at treating relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) in adult patients [1] Group 1 - The drug is classified as a therapeutic biological product under category 3.2 [1] - The application is specifically for adult patients suffering from relapsed or refractory precursor B-cell acute lymphoblastic leukemia [1]

证券代码：600196 股票简称：复星医药 编号：临 2025-150 二、该产品的基本信息及研究情况 该产品系复星凯瑞基于自 Kite Pharma,Inc.（系 Gilead Sciences, Inc.的控 股子公司）引进的 Tecartus 经技术转移并获授权于中国（包括香港、澳门）进行开 发及本地化生产的靶向 CD19 的 CAR-T 细胞治疗产品。Tecartus 已于 2020 年 7 月及 12 月先后于美国、欧洲获批上市。 截至本公告日期（即 2025 年 9 月 24 日，下同），该产品的另一适应症（即用 于治疗既往接受过二线及以上治疗后复发或难治性套细胞淋巴瘤（r/r MCL）成人患 者）于中国境内（不包括港澳台地区，下同）处于桥接临床试验阶段。 截至 2025 年 8 月，本集团（即本公司及控股子公司/单位，下同）现阶段针对 该产品的累计研发投入约为人民币 1.83 亿元（未经审计）。 截至本公告日期，包括复星凯瑞的奕凯达（阿基仑赛注射液）在内，已有多款 CAR-T 细胞治疗产品于中国境内获批上市，由于数据库覆盖的销售渠道等原因，其 整体市场情况无法通过公开数据库准确查询。 上海复星医 ...

Core Viewpoint - Fosun United Health Insurance Co., Ltd. has successfully completed a strategic capital increase of 810 million yuan, raising its registered capital from 694.44 million yuan to 1.01085 billion yuan, marking a significant milestone in its capital strength and shareholder structure [1][2]. Group 1: Capital Increase Details - On September 22, 2023, Fosun United Health received approval from the Guangdong Financial Regulatory Bureau for a capital increase of 810 million yuan [1]. - The capital increase involved new shareholders, including the International Finance Corporation (IFC) and the Asian Development Bank (ADB), while existing shareholder Fosun Pharma increased its stake from 14% to 20.05% [1]. - The capital increase is expected to provide a solid foundation for the company's future high-quality development and business expansion [1]. Group 2: Financial Performance - Since its establishment in January 2017, Fosun United Health has seen a continuous expansion in premium income, with insurance business revenue growing from 5.9 million yuan in 2017 to 5.226 billion yuan in 2024 [2]. - In the first half of 2025, the company achieved insurance business revenue of 3.642 billion yuan, representing a year-on-year growth of 31.09%, and net profit of 33 million yuan, marking a return to profitability [2]. - Despite previous attempts at capital increases in 2018, 2019, 2021, and 2023 failing, the company received cash donations from shareholders to supplement its capital during that period [2]. Group 3: Solvency Position - As of the end of 2022, the core solvency adequacy ratio of Fosun United Health dropped to 56.77%, and the comprehensive solvency adequacy ratio fell to 113.55%, nearing regulatory limits [3]. - By the end of 2023, these solvency ratios further declined to 55.34% and 110.67%, respectively [3]. - Following the capital increase in April 2024, the company's solvency ratios improved significantly, with the core solvency adequacy ratio reaching 114.88% and the comprehensive solvency adequacy ratio at 166.85% by June 2025 [3].

Core Insights - Fosun United Health Insurance has officially received approval from the Guangdong Regulatory Bureau of the National Financial Supervisory Administration for a capital increase of 810 million RMB, raising its registered capital from 694.44 million RMB to 1.01085 billion RMB [1][3] Capital Increase Details - The capital increase marks a significant milestone for Fosun United Health Insurance, enhancing its capital strength, shareholder structure, and solvency [3] - A total of 316.41 million shares will be issued at a price of 2.56 RMB per share, based on the total capital increase of 810 million RMB [3] - Major shareholders, including Shanghai Fosun Pharmaceutical Group, International Finance Corporation (IFC), and Asian Development Bank (ADB), will each subscribe to 105.47 million shares [3] - Post-increase, Fosun Pharmaceutical will hold 20.05% of the shares, while IFC and ADB will each hold 10.43%, making them the second-largest shareholders [3] Shareholder Background - IFC, as the lead investor, is a member of the World Bank Group and focuses on private sector development in emerging markets [4] - ADB has extensive experience in health services and will support the company in building health service networks and developing inclusive insurance products [4] - Fosun Pharmaceutical's extensive experience in the healthcare industry will facilitate the integration of insurance and medical services, enhancing service professionalism and precision [4] Financial Performance - Since its establishment in January 2017, Fosun United Health Insurance has seen a continuous increase in premium income, achieving profitability since 2021 [5] - In 2024, the company reported insurance business revenue of 5.226 billion RMB, a 27% year-on-year increase, and a net profit of 40 million RMB, up over 80% year-on-year [5] - The company’s health insurance premium income reached 5.2 billion RMB in 2024, with significant contributions from critical illness and nursing insurance products [5] Solvency Improvement - The recent capital increase will alleviate the long-term downward pressure on the company's solvency [6] - As of the end of 2023, the core solvency ratio had dropped to 55.34%, and the comprehensive solvency ratio to 110.67%, nearing regulatory limits [6] - Following the capital increase, the core solvency ratio and comprehensive solvency ratio are expected to reach 117% and 173%, respectively, by the end of 2024 [6] Future Plans - The company plans to enhance resource investment post-capital increase, focusing on expanding coverage and optimizing product offerings in critical areas such as major diseases and chronic disease management [7] - Leveraging the expertise of international shareholders and Fosun Pharmaceutical's medical resources, the company aims to upgrade service experiences and provide comprehensive health support from prevention to rehabilitation [7]

Group 1 - The cell immunotherapy sector experienced a decline of 2.75%, ranking among the top losers in the concept sector, with ST Zhongzhu hitting the daily limit down [1] - Major stocks within the cell immunotherapy sector that saw significant declines include Zhaoyan New Drug, Jimin Health, and Boteng Co., with respective drops of 6.04%, 5.45%, and 5.34% [1][2] - The sector faced a net outflow of 1.61 billion yuan from main funds, with 48 stocks experiencing outflows, and six stocks seeing outflows exceeding 100 million yuan, led by Hengrui Medicine with a net outflow of 293 million yuan [2] Group 2 - The top gainers in today's concept sectors included the SMIC concept with a rise of 1.22% and the National Big Fund holding with an increase of 1.08% [2] - The main inflows were observed in stocks such as Betta Pharmaceuticals, Chutian Technology, and Rongchang Bio, with net inflows of 35.97 million yuan, 21.30 million yuan, and 14.08 million yuan respectively [4] - The overall market sentiment reflected a mixed performance across various sectors, with notable declines in the Huawei Pangu and MLOps concepts, down 3.69% and 3.31% respectively [2]